ABcann Global Recruits Dr. Michael Shannon as Chief Medical Consultant
June 29 2017 - 8:20AM
ABcann Global Corporation (TSX-V:ABCN) ("ABcann"
or the "Company") is pleased to announce that it has retained the
services of Dr. Michael Shannon as its Chief Medical
Consultant.
Dr. Shannon served in the Canadian Armed Forces
for 31 years, and also as Deputy Surgeon General for Canada. In
1996, he assumed responsibilities within Health Canada for
re-organizing the Canadian blood system and the development of a
new corporate entity dedicated exclusively to the management of
blood services in Canada. He was then appointed Director General
for the Laboratory Centre for Disease Control. In December 2000,
Dr. Shannon left the Federal Government to pursue a new career in
industry. In that capacity, he simultaneously directed a Phase III
clinical trial in Canada, the United States and Great Britain for
an artificial blood substitute product. Dr. Shannon has been
actively engaged in medical bio-oxidative (O3 based) research since
1987 and has served as the Senior Medical Advisor to Medizone
International since 2002. In October 2008, he was appointed the
President of the Canadian Foundation for Global Health.
"In the future we plan to participate in a
number of clinical trials involving different modes of delivery as
well as various research projects with potentially significant
clinical implications in order to facilitate the acceptance of
cannabis treatment by the mainstream medical community. Dr.
Shannon’s experience and expertise, along with his established
credibility, will help us through this process as we move these
developments forward," says Aaron Keay, CEO of ABcann.
“Our sophisticated growing technology allows us
to produce a consistent product, from batch to batch. That
consistency is needed to be able to couple our technology with
technologies for controlled-dose delivery in order to perform the
trials necessary to develop the evidence to bring cannabis
treatment into the mainstream," says Ken Clement, Executive
Chairman and Founder of ABcann. "We are delighted and extremely
fortunate to be able to add Dr. Shannon to our team."
About ABcann Global Corporation
(TSX.V:ABCN):
ABcann was one of the first companies to obtain
a production license under the Marijuana for Medical Purposes
Regulations, which it received on March 21, 2014. It obtained a
sales license on December 31, 2015. ABcann’s flagship facility, in
Napanee, Ontario, contains proprietary plant-growing technology,
including environmentally-controlled chambers capable of monitoring
and regulating all variables in the growing process. This approach
and the systems in place allow ABcann to produce organically grown
and pesticide-free, high-yielding plants, which, in turn, can
generate high-quality products that are consistent from batch to
batch. ABcann is able to control environmental and nutrient
demands, tailor-made for a particular strain of cannabis, without
the variation that is typical when producing large quantities in
less-controlled, larger rooms and greenhouse-type structures.
ABcann’s modular approach to systems technology eliminates scale-up
risk and allows ABcann to locate anywhere in the world and maintain
consistency and quality of product.
ABcann is expanding capacity in its current
facility to approximately 30,000 sq ft and concurrently undertaking
expansion into a new 150,000 sq ft facility in Napanee. ABcann is
pursuing opportunities in Germany, Australia and other
jurisdictions as well as exploring the development of multiple
delivery vehicles.
ON BEHALF OF THE BOARD OF DIRECTORS
"Aaron Keay"
Aaron Keay CEO and Director
For further information, please contact Aaron Keay by phone at
(604) 323-6911 or by email at aaron@ABcannglobal.com, or Leo
Karabelas by phone at 416 543-3120 or by email
at leo.k@ABcannglobal.com
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this release are
forward-looking statements, which are statements that are not
purely historical, including any statements regarding beliefs,
plans, expectations or intentions regarding the future. Forward
looking statements in this news release include statements relating
to: ABcann’s planned clinical trials and research projects, the
potential clinical implications of same; ABcann’s ability to
develop evidence that will support the acceptance of cannabis
treatment by the medical community; and the scope of the Company’s
proposed expansions at its Vanluven and Kimmett facilities. Such
statements are subject to risks and uncertainties that may cause
actual results, performance or developments to differ materially
from those contained in the statements, including: (i) delays or
other factors that prevent the Company from conducting its planned
clinical trials and other proposed research projects; (ii) changes
to applicable legislation or regulatory requirements; (iii) changes
to the anticipated costs of the expansions that require the Company
to obtain additional capital or modify its development plans; and
(iv) other factors beyond the Company's control. No assurance can
be given that any of the events anticipated by the forward-looking
statements will occur or, if they do occur, what benefits the
Company will obtain from them. Readers are urged to consider these
factors, and the more extensive risk factors included in the
Company’s filing statement dated March 31, 2017 which is available
on SEDAR, carefully in evaluating the forward-looking statements
contained in this news release and are cautioned not to place undue
reliance on such forward-looking statements, which are qualified in
their entirety by these cautionary statements. The forward-looking
statements in this news release are made as of the date hereof and
the Company disclaims any intent or obligation to update publicly
any such forward-looking statements, whether as a result of new
information, future events or results or otherwise, except as
required by applicable securities laws.
Abcann Global Corporation (TSXV:ABCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Abcann Global Corporation (TSXV:ABCN)
Historical Stock Chart
From Jul 2023 to Jul 2024